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Abstract
Myeloﬁbrosis (MF), a Philadelphia chromosome-negative myeloproliferative neoplasm, is characterized by progressive
bone marrow ﬁbrosis and ineffective hematopoiesis. Clinical hallmarks include splenomegaly, anemia, and debilitating
symptoms. In 2 randomized phase III studies, the Janus kinase (JAK) 1/JAK2 inhibitor ruxolitinib signiﬁcantly improved
splenomegaly and disease-related symptoms compared with placebo (Controlled Myeloﬁbrosis Study with Oral JAK
Inhibitor Treatment [COMFORT-I]) or best available therapy (COMFORT-II) in patients with intermediate-2 or high-risk
MF. Although ruxolitinib therapy was associated with dose-dependent anemia and thrombocytopenia, these adverse
events rarely led to treatment discontinuation. This update of the clinical effects of ruxolitinib in patients with MF was
based on original articles and meeting abstracts published after the primary publication of the COMFORT trials in March
2012. Long-term follow-up data from the COMFORT trials and clinical experience with ruxolitinib in unselected patient
populations suggest that improvement of splenomegaly and symptoms is durable. Patients beneﬁt from ruxolitinib
therapy across subgroups deﬁned by age, MF type, risk category, performance status, JAK2 V617F mutation status,
extent of splenomegaly, or presence of cytopenias. In COMFORT-I, platelet counts stabilized with dose adjustments,
and hemoglobin levels gradually recovered to slightly below baseline after the ﬁrst 8 to 12 weeks of therapy. After initial
increases, the need for red blood cell transfusions decreased to a level similar to that found in the placebo group. The
2-year follow-up data from the COMFORT trials suggest that patients with intermediate-2 or high-risk MF receiving
ruxolitinib therapy may have improved survival compared with those receiving no (placebo) or traditional therapy.
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Myeloﬁbrosis (MF) is a pathologic entity occurring in the form of
primary MF (PMF), post-polycythemia vera (PV) MF, or post-
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2152-2650 ª 2013MF comprises a group of related disorders that constitute or develop
from a Philadelphia chromosome-negative myeloproliferative
neoplasm (MPN). MF is characterized by progressive bone marrow
ﬁbrosis and ineffective hematopoiesis.1-3 Although PMF, PV, and
ET have distinct disease characteristics and diagnostic criteria,4
secondary development of MF in patients with PV or ET results
in disorders with clinical and laboratory characteristics virtually
indistinguishable from those of PMF.1,3 Typical clinical manifes-
tations of MF include anemia and splenomegaly, which are conse-
quences of ineffective and extramedullary hematopoiesis, and
debilitating symptoms (eg, fatigue, night sweats, bone pain, fever,
pruritus, and weight loss) resulting from disease-related systemic
inﬂammation and excessive catabolism.2,3,5,6 The estimated preva-
lence of MF—including PMF and secondary development from PV
or ET—in the United States is 3.6 to 5.7 cases per 100,000 per-
sons.7 For patients with PMF, the median age at the time of
diagnosis is approximately 65 years.8,9
A hallmark of MPNs, including PMF, is aberrant myeloprolif-
eration associated with dysregulated Janus kinase (JAK)-signalThe Authors. Published by Elsevier Inc.
http://dx.doi.org/10.1016/j.clml.2013.09.006
Open access under CC BY-NC-ND license.
transducer and activator of transcription (STAT) signaling.10
Patients with MPNs carry somatic mutations in hematopoietic
stem cells that result in constitutive activation or overactivation of
JAK-STAT pathways,11,12 which are essential in normal hemato-
poiesis.13 Although the gain-of-function mutation JAK2 V617F is
the most prevalent of these mutations—present in approximately
60% of patients with PMF and ET, and at least 95% of patients
with PV11—an increasing number of mutations that directly or
indirectly affect JAK-STAT signaling, including mutations in ge-
netic and epigenetic regulators, have been associated with MPNs,
and patients may have multiple neoplastic stem cell clones.11,12,14
When present, the JAK2 V617F mutation appears not to be
the disease-initiating event,15 but it may contribute to MPN
disease phenotype and manifestations.16-18 In patients with MF,
dysregulated JAK-STAT signaling not only is involved in the
pathogenesis of myeloproliferation but also appears to be associated
with secondary pathogenic phenomena, particularly the excess
production of inﬂammatory cytokines, which is believed to be
associated with MF-related symptoms and is sensitive to JAK
inhibition.19,20
The prognoses of patients with PMF vary widely depending on
age, presence of symptoms and anemia, leukocyte and platelet
counts, percentage of circulating blasts, and karyotype.8,21,22 Based
on the number of prognostic factors, a patient’s risk status is clas-
siﬁed as low (no risk factors), intermediate-1, intermediate-2, or
high. Although risk classiﬁcation and prognostic estimates vary with
the prognostic scoring system used, the median survival time is < 2
years for high-risk patients and 3 to 7 years for intermediate-risk
patients with PMF.8,21,22
Before the recognition of the critical role of aberrant JAK-STAT
signaling in the pathophysiology of MF, available treatment options
in general were palliative and associated with limited and transient
responses.23 Treatment with the oral JAK1/JAK2 inhibitor rux-
olitinib has been evaluated in patients with intermediate-2 or high-
risk MF, including PMF, post-PV MF, and post-ET MF in 2 large
randomized phase III studies, the double-blind placebo-controlled
COMFORT (Controlled Myeloﬁbrosis Study with Oral JAK In-
hibitor Treatment)-I study24 and the COMFORT-II study, which
compare the effects of ruxolitinib therapy and best available therapy
(BAT).25 In both, ruxolitinib therapy was associated with signiﬁcant
improvements in splenomegaly and MF-associated symptoms
compared with the controls. Mean reductions from baseline in
spleen volume with ruxolitinib therapy were approximately 30% in
both studies, whereas spleen volumes increased in the placebo group
in COMFORT-I and in the BAT group in COMFORT-II.24,25 In
COMFORT-I, ruxolitinib therapy also was associated with a mean
decrease of 46% in MF-related symptoms, based on total symptom
score (TSS) assessed using the modiﬁed MF Symptom Assessment
Form version 2.0—compared with a 42% increase in TSS in the
placebo group.24 Furthermore, compared with placebo, ruxolitinib
therapy was associated with signiﬁcant improvements in measures of
the European Organisation for Research and Treatment of Cancer
Quality-of-Life Questionnaire Core 30 (EORTC QLQ-C30),
including global health status/quality of life (QoL) and physical,
role, emotional, and social functioning.24 Patients treated with
ruxolitinib in COMFORT-II experienced clinically meaningful
improvements in symptoms and QoL measures including fatigue,dyspnea, insomnia, appetite loss, and physical- and role-functioning
scales, as evaluated using the EORTC QLQ-C30, whereas BAT was
generally associated with no change or symptom worsening.25,26
Symptom improvements with ruxolitinib therapy were accompa-
nied by decreases in the plasma levels of proinﬂammatory bio-
markers.24,25 No major changes in bone marrow histomorphology
were observed.25 Although ruxolitinib was generally well tolerated
in both trials, patients in the ruxolitinib groups experienced
increased rates of dose-dependent anemia and thrombocytopenia
compared with that of the control groups; however, these events
rarely led to treatment discontinuations.24,25
The purpose of this review is to provide an update of the clinical
effects of ruxolitinib in patients with myeloﬁbrosis. The updated
information was obtained from original articles and abstracts from
professional society presentations published in the 12 months
following the primary publication of the clinical data from the
COMFORT trials in March 2012.
Discussion
Effect on Survival
In the publications of the primary results of the COMFORT
studies, the 1-year follow-up data from COMFORT-I suggested
that ruxolitinib therapy was associated with improved survival in
patients with intermediate-2 or high-risk MF relative to that of
the placebo group.24 However, this was not seen with ruxolitinib
therapy versus BAT in COMFORT-II (Table 1).25 The 2-year
follow-up data from both COMFORT studies were presented at
the annual meeting of the American Society of Hematology in
December 2012.27,28 Kaplan-Meier analyses of overall survival
were based on the intended treatment at randomization and did
not take into account crossover of patients from the control to the
ruxolitinib groups, which was permitted in both trials according
to protocol-speciﬁed criteria of disease progression. In both trials,
the 2-year analyses showed a reduction in the risk of death
for patients randomized to ruxolitinib compared with those ran-
domized to the control groups (Table 1). The 2-year survival data
from COMFORT-I conﬁrmed those reported after 1 year of
follow-up, suggesting that ruxolitinib therapy, relative to placebo,
may be associated with prolonged survival in patients with
intermediate-2 or high-risk MF.24 Improved survival was seen,
although all patients originally randomized to the placebo group
had discontinued or crossed over to ruxolitinib therapy at the
time of the 2-year analysis. The 2-year survival data from
COMFORT-II28,29 are the ﬁrst indication of improved survival of
patients who received ruxolitinib therapy rather than BAT
(Table 1). Possible reasons that improved survival with ruxolitinib
therapy relative to BAT was not observed at earlier follow-up
times25 include the 2:1 randomization scheme in favor of rux-
olitinib therapy and potentially biased survival estimates caused
by the relatively high proportion of patients in the BAT arm
who were censored (27.4% vs. 14.4% in the ruxolitinib arm)
because of a lack of relevant follow-up information.29
Cachexia-related persistent weight loss and decreases in total
cholesterol are common in patients with MF and are associated
with shortened survival.8,30,31 In both COMFORT studies, rux-
olitinib therapy was associated with substantial median weight
gains, whereas placebo treatment and BAT were associated withClinical Lymphoma, Myeloma & Leukemia December 2013 - 639
Table 1 Effect of Ruxolitinib on Overall Survival in COMFORT-I and COMFORT-II
Study Treatment Group Median Follow-up, wk HR (95% CI) P
COMFORT-I24,27 Ruxolitinib (n ¼ 155) 3224 0.67 (0.30-1.50) .33
vs. placebo (n ¼ 154) 5124 0.50 (0.25-0.98) .04a
10227 0.58 (0.36-0.95) .028a
COMFORT-II25,28 Ruxolitinib (n ¼ 146) 5225 0.70 (0.20-2.49)
vs. BAT (n ¼ 73) 6125 1.01 (0.32-3.24)
11228,29 0.51 (0.27-0.99) .041a
Abbreviations: BAT ¼ best available therapy; CI ¼ conﬁdence interval; COMFORT ¼ Controlled Myeloﬁbrosis Study with Oral JAK Inhibitor Treatment; HR ¼ hazard ratio.
aP values for this unplanned analysis are descriptive and not adjusted for multiple comparisons.
Table 2 Long-Term Effects of Ruxolitinib on Spleen Volume and
EORTC QLQ-C30 Global Health Status/Quality of Life in
COMFORT-I27
Change From Baseline, Mean
(SEM)
Week Ruxolitinib Placebo
Spleen volume
24 31.6 (1.6) 8.2 (1.5)
48 31.6 (2.1) NA
72 34.1 (2.5) NA
96 34.9 (3.0) NA
EORTC QLQ-C30 Global Health Status/Quality of Lifea
24 12.3 (2.2) 3.7 (2.1)
48 13.6 (2.2) NA
72 14.1 (2.5) NA
96 13.0 (2.4) NA
Abbreviations: COMFORT ¼ Controlled Myeloﬁbrosis Study with Oral JAK Inhibitor Treatment;
EORTC ¼ European Organisation for Research and Treatment of Cancer; NA ¼ not available;
QLQ ¼ Quality of Life Questionnaire; SEM ¼ standard error of the mean.
aIncrease by > 10 points indicates clinically meaningful improvement.
Adapted with permission of American Society of Hematology, from Long-term outcome of
ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume,
improvements in quality of life, and overall survival advantage in COMFORT-I. Verstovsek S,
et al., Blood 120, 2013; permission conveyed through Copyright Clearance Center, Inc.
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640 -weight decreases and no substantial changes in weight, respec-
tively.24,25 A post hoc analysis of longer-term COMFORT-I data
presented at the 53rd annual meeting of the American Society of
Hematology in December 2012 suggests that ruxolitinib-mediated
alleviation of cachexia and improvement in total cholesterol may
contribute to the improved survival seen in patients receiving
ruxolitinib therapy. Patients in the ruxolitinib group with greater
than median weight gains had a reduced risk of death compared
with those who achieved smaller weight gains (hazard ratio [HR],
0.40; 95% conﬁdence interval [CI], 0.18-0.90; P ¼ .022).32
Furthermore, 97% of patients randomized to the ruxolitinib
group experienced metabolic improvement in the form of an in-
crease in total cholesterol, and greater than median increases in
total cholesterol were associated with improved survival prognosis
compared with smaller increases (HR, 0.46; 95% CI, 0.21-1.01;
P ¼ .048).32
Efﬁcacy in Spleen Size Reduction and Symptom
Improvement
Durability of Treatment Response. The 2-year follow-up data from
the 2 COMFORT trials demonstrated that ruxolitinib-mediated
reductions in splenomegaly and symptom burden were dura-
ble.27,28 In COMFORT-I, 134 of 155 patients originally ran-
domized to the ruxolitinib group continued treatment after the
primary data analysis at week 24, and 100 patients remained on
treatment at the time of the 2-year analysis.27 Patients randomized
to the ruxolitinib group who were followed for a median period of
102 weeks had mean reductions from baseline in spleen volume of
32% at week 24 and 35% at week 96 (Table 2), and for those who
originally met the primary endpoint of a  35% reduction in spleen
volume at week 24, the median response duration was 108 weeks.
The mean increase from baseline in EORTC QLQ-C30 global
health status/QoL was 12.3 points at week 24 and 13.0 points at
week 96 (Table 2), with an increase of at least 10 points indicating a
clinically meaningful improvement.27
In COMFORT-II, 81 of 146 patients originally randomized to
the ruxolitinib group remained on treatment at the time of the
2-year analysis.28 At a median follow-up of 112 weeks, a total of 70
patients (48%) had achieved a  35% reduction in spleen volume
at any time during the trial. These reductions were sustained with
continued therapy. With the median duration of spleen response
not reached at the time of the analysis, the estimated probabilities of
maintaining response at weeks 48 and 84 were 75% (95% CI, 61%-
84%) and 58% (95% CI, 35%-76%), respectively.28Clinical Lymphoma, Myeloma & Leukemia December 2013Clinical Beneﬁts in Speciﬁc Patient Populations. Results of recent
COMFORT-I subgroup analyses show that patients treated with
ruxolitinib experienced improvements in spleen size and TSS
across subgroups deﬁned by MF subtype, age group, International
Prognostic Scoring System (IPSS) risk, JAK2 V617F mutation
status or various baseline parameters, such as Eastern Cooperative
Oncology Group (ECOG) performance status, hemoglobin value,
platelet count, palpable spleen size, spleen volume quartile, or TSS
quartile (Fig. 1).33 Across COMFORT-I subgroups, mean re-
ductions from baseline in spleen volume in patients treated with
ruxolitinib ranged from 29.2% to 33.9%, whereas mean reductions
from baseline in TSS ranged from 36.2% to 56.7%.33 Previous
results from COMFORT-II showed that ruxolitinib overall was
more effective than BAT at reducing spleen volume across sub-
groups deﬁned by gender, age, mutation status, IPSS risk category,
baseline spleen size, MF subtype, or ruxolitinib starting dose.34
In a post hoc analysis of spleen volume reductions and patient-
reported outcomes in COMFORT-I, ruxolitinib-treated patients
achieving  10% reduction in spleen size had signiﬁcant
Figure 1 Percentage Change in Spleen Volume (A) and Total Symptom Score (B) From Baseline to Week 24, by COMFORT-I Patient
Subgroup33
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Dashed lines represent the mean percentage change from baseline for overall treatment group.24
Abbreviations: COMFORT ¼ Controlled Myeloﬁbrosis Study with Oral JAK Inhibitor Treatment; ECOG PS ¼ Eastern Cooperative Oncology Group performance status; Hb ¼ hemoglobin level; Int-2 ¼
Intermediate-2; IPSS ¼ International Prognostic Scoring System; JAK ¼ Janus kinase; MF ¼ myeloﬁbrosis; PET ¼ post-essential thrombocythemia; PMF ¼ primary myeloﬁbrosis; PPV ¼ post-
polycythemia vera; SEM ¼ standard error of the mean. (Reprinted with permission from Blackwell Publishing Ltd. Verstovsek S, et al. The clinical beneﬁt of ruxolitinib across patient subgroups:
analysis of a placebo-controlled, phase III study in patients with myeloﬁbrosis. Br J Haematol 2013; 161:508-16. ª 2013 Blackwell Publishing Ltd.)
Hagop M. Kantarjian et alimprovements versus those in the placebo group in TSS (P < .001),
total abdominal (P ¼ .001) and nonabdominal (P < .001) symp-
toms, and other patient-reported outcomes, including global health
status/QoL (P< .001), Patient Global Impression of Change (PGIC)
scores (P < .001), and Patient-Reported Outcomes Measurement
Information System (PROMIS) fatigue scores (P < .001).35 How-
ever, even patients with < 10% reduction in spleen size experiencedclinically meaningful improvements in TSS, total abdominal and
nonabdominal symptoms, and PGIC scores with ruxolitinib versus
placebo treatment.35
An analysis of COMFORT-I patients stratiﬁed by baseline values
of palpable spleen length or TSS showed that ruxolitinib therapy
was effective in reducing spleen volume and symptom burden
regardless of spleen size or symptom severity, whereas patientsClinical Lymphoma, Myeloma & Leukemia December 2013 - 641
Table 3 Incidence of Splenectomy During Clinical Studies of Ruxolitinib37
Patient Group n Patient-years Splenectomies, n
Splenectomies per 100
Patient-years, n
Assigned to ruxolitinib 459 818.0 9 1.10
BAT or placebo 224 170.7 5 2.93
Abbreviation: BAT ¼ best available therapy.
Republished with permission of American Society of Hematology, from Effect of ruxolitinib on the incidence of splenectomy in patients with myelofibrosis: a retrospective analysis of data from
ruxolitinib clinical trials. Verstovsek S, et al, Blood 120, 2013; permission conveyed through Copyright Clearance Center, Inc.
Figure 2 Mean Percentage Change From Baseline in (A)
Platelet Counts and (B) Hemoglobin Levels Over
Time39
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The graphs for this ﬁgure, originally part of a poster presentation [39], have now been published
(Verstovsek, et al. Management of cytopenias in patients with myeloﬁbrosis treated with
ruxolitinib and effect of dose modiﬁcations on efﬁcacy outcomes. Onco Targets Ther 2013;6:1-9
[Published by Dove Press]).
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642 -receiving placebo experienced disease progression across all sub-
groups.36 For this analysis, a nonlinear mixed model that best ﬁtted
individual patient data was used to predict placebo-associated
changes in spleen volume for patients who crossed over to rux-
olitinib therapy, whereas last observations were carried forward to
impute missing TSS data. Based on this analysis, patients in
COMFORT-I who started ruxolitinib therapy at a less advanced
stage of the disease were likely to achieve a better clinical status at a
given time point in terms of absolute spleen size and symptom
severity than those initiating therapy at a more advanced disease
stage.36 The results of this hypothesis-generating analysis seem to
suggest that patients with clinically signiﬁcant splenomegaly or MF-
related symptoms generally may beneﬁt from early intervention, but
further prospective studies are needed.
In light of the efﬁcacy of ruxolitinib therapy in reducing
splenomegaly and symptom burden, a retrospective analysis across
ruxolitinib clinical trials (phase I/II open-label and the 2 phase III
COMFORT studies) was conducted to assess whether ruxolitinib
therapy affected the incidence of splenectomy.37 The results showed
that the incidence of splenectomy among patients treated with
ruxolitinib was almost 3 times lower than that among patients
randomized to placebo or BAT in the COMFORT trials
(Table 3).37 This analysis, which was based on intent-to-treat
populations, likely underestimated the true incidence of splenec-
tomy associated with placebo treatment and BAT because of the
large proportion of patients in the COMFORT studies who crossed
over from the control arms to ruxolitinib therapy.24,25 The ﬁndings
of this analysis suggest that ruxolitinib therapy may prevent or delay
the potential need for splenectomy in patients with severe spleen-
related symptoms.
Effects of Dose Modiﬁcations. A dose-response post hoc analysis
from COMFORT-I showed that most patients randomized to
ruxolitinib achieved a ﬁnal titrated dose (deﬁned as average daily
dose from weeks 21-24) of 10 mg twice daily or greater, including
most patients with platelet counts of 100 to 200  109/L at
baseline.38 Reductions in splenomegaly and symptom burden
similar to those observed in the primary analysis were seen in patient
groups with mean ﬁnal titrated doses of 10 mg twice daily and
greater. The authors concluded that patients who received a dose of
at least 10 mg twice daily achieved clinically meaningful reductions
in spleen size and improvements in fatigue as well as other MF-
related symptoms.38
Safety and Tolerability
Although risks of anemia and thrombocytopenia remain main
concerns in the treatment of patients with ruxolitinib, the 2-yearClinical Lymphoma, Myeloma & Leukemia December 2013safety data from the COMFORT studies showed that there were
no unexpected safety or tolerability issues with longer-term therapy
past the time frame for the primary analysis.27,28 Among all patients
randomized to the ruxolitinib group in COMFORT-I, grade 3 or 4
anemia, regardless of baseline hemoglobin level, was reported in
37.4% and 14.8% of patients, respectively, at a median follow-up of
102 weeks. Grade 3 or 4 thrombocytopenia was reported in 11.0%
and 5.2% of patients, respectively. These rates were similar to those
Table 4 Summary of Hematology and Efﬁcacy in Study 258 (Interim Results)43 and COMFORT-I24
Ruxolitinib Placebo
Study 258 (N[41) COMFORT-I (N[155) COMFORT-I (N[154)
Total daily dose at week 12 / week 24, mg 15.1 / 19.1 30.4 / 29.6 0
Hematology
Mean baseline values
Platelet count, 109/L 73 321 280
Hemoglobin level in patients with
no transfusions, g/L
108 123 115
Mean change from baseline to week 12 / week 24
Platelet count, 109/L 1.0 / 5.3 130 / 159 9.1 / 11.2
Hemoglobin level, g/L 1.8 / 0.2 18 / 11 þ1.3 / þ1.9
Efﬁcacy
Percent of patients
 50% reduction in TSS 36 46 5.3
 35% reduction in spleen volume 33 42 0.7
“Much” or “very much improved” on PGIC 59 67 11
Mean change from baseline
EORTC QLQ-C30 Fatigue Subscalea 23.4 14.8 1.8
EORTC QLQ-C30 Global Health Status/Quality of
Lifeb
16.2 12.3 3.4
Abbreviations: COMFORT ¼ Controlled Myeloﬁbrosis Study with Oral JAK Inhibitor Treatment; EORTC ¼ European Organisation for the Treatment of Cancer; PGIC ¼ Patient Global Impression of
Change; QLQ ¼ Quality of Life Questionnaire; TSS ¼ total symptom score.
aNegative values indicate improvement.
bPositive values indicate improvement.
Republished with permission of American Society of Hematology, from Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50-100 x 10 9/L): a
comparison to patients with normal or high starting platelet counts. Talpaz M, et al., Blood 120, 2013; permission conveyed through Copyright Clearance Center, Inc.
Hagop M. Kantarjian et alreported in the primary analysis at a median follow-up of 32 weeks,
ie, grade 3 or 4 anemia in 45.2% and grade 3 or 4 thrombocyto-
penia in 12.9% of patients.24 Rates of nonhematologic adverse
events adjusted for increased follow-up duration were similar to
those seen at the time of the primary data analysis. After the report
of 2 cases of secondary acute myeloid leukemia among patients
treated with ruxolitinib at the time of the primary analysis, no
additional cases of acute myeloid leukemia in this patient group
were reported.27
At a median follow-up of 112 weeks, the most common new or
worsened grade 3 or 4 hematologic abnormalities during random-
ized treatment in COMFORT-II were anemia (ruxolitinib therapy,
40.4%; BAT, 23.3%), lymphopenia (ruxolitinib therapy, 22.6%;
BAT, 31.5%), and thrombocytopenia (ruxolitinib therapy, 9.6%;
BAT, 9.6%).28 In the ruxolitinib arm, mean hemoglobin levels
decreased over the ﬁrst 12 weeks of treatment and then recovered
after week 24 to levels that were similar to those observed with
BAT. Mean monthly red blood cell transfusion rates also were
similar in the 2 treatment groups. Most nonhematologic adverse
events were grade 1 or 2. No new nonhematologic adverse events
associated with ruxolitinib therapy that occurred in  10% of pa-
tients were observed, beyond those that were observed previously.
This analysis included ruxolitinib treatment during the extension
phase of patients originally randomized to the BAT group.28
The dose-dependent risks of anemia and thrombocytopenia
associated with ruxolitinib are a consequence of the drug’s mecha-
nism of action, as erythropoietin and thrombopoietin both signalthrough JAK2.10 However, results from COMFORT-I showed that
treatment-related events of anemia or thrombocytopenia generally
can be managed effectively using dose reductions, brief treatment
interruptions, and red blood cell transfusions (for anemia) without
compromising efﬁcacy or leading to permanent treatment discon-
tinuation.24,39 Time course analyses showed that most grade  3
anemia or thrombocytopenia occurred during the ﬁrst 8 to 12 weeks
of treatment with ruxolitinib, parallel to mean decreases in platelet
counts and hemoglobin levels.24,39 Mean platelet counts subse-
quently stabilized and hemoglobin values gradually recovered to
levels slightly below baseline values (Fig. 2). Consistent with the
recovery of hemoglobin values, the proportion of patients receiving
red blood cell transfusions gradually decreased to the level seen in
the placebo group, after increasing during the ﬁrst 8 weeks of
treatment.24,39
Isolated cases of a ruxolitinib withdrawal syndrome during the
ruxolitinib phase I/II study were reported based on the occurrence
of acute or severe disease-related symptoms after treatment
discontinuation.40 However, these cases included patients who
discontinued ruxolitinib therapy during acute intercurrent illnesses,
and it has not been established whether discontinuation of therapy
contributed to the clinical course in these patients.40,41 In the
COMFORT-I primary analysis, myeloﬁbrosis-related symptom
burden, as measured by TSS, was shown to return to baseline levels
over a period of approximately 1 week following treatment inter-
ruption; however, a closer inspection of the pattern of adverse events
following treatment interruption or discontinuation suggested thatClinical Lymphoma, Myeloma & Leukemia December 2013 - 643
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644 -ruxolitinib was not associated with a withdrawal syndrome.42 No
case of a ruxolitinib withdrawal syndrome was reported in the 2-year
follow-up as well.27 Nonetheless, because it may be difﬁcult to
distinguish between symptoms returning or worsening because of
drug withdrawal and symptoms of disease progression, gradual
tapering of the dose of ruxolitinib should be considered when dis-
continuing therapy for reasons other than thrombocytopenia.41
Ruxolitinib Therapy in Patients With Low Platelet
Counts
The COMFORT studies excluded patients with baseline platelet
counts below 100  109/L. Two early-phase clinical studies are
underway to determine the optimal dosing strategy for ruxolitinib in
patients with platelet counts of 50  109/L to 100  109/L.43,44
Interim results of a phase II study in patients with baseline
platelet counts of 50  109/L to 100  109/L (Study 258,
NCT01348490), who received a starting dose of 5 mg twice daily,
showed that most patients who complete 24 weeks of treatment
attained ﬁnal doses of 10 mg twice daily or greater,43 a dosage
regimen that has been shown to provide clinically meaningful
reductions in spleen size and improvements in fatigue and other
MF-related symptoms.38 No treatment discontinuation attributable
to thrombocytopenia or bleeding events occurred, and the pre-
liminary efﬁcacy results for ruxolitinib are consistent with the
ﬁndings from COMFORT-I (Table 4).43 The authors concluded
that using a low starting dose (5 mg twice daily) with subsequent
uptitration to  10 mg twice daily under careful monitoring may be
a useful strategy to optimize tolerability and maximize the beneﬁt of
ruxolitinib in patients with low platelet counts.43 Preliminary ﬁnd-
ings from EXPAND (Evaluating RuXolitinib in Patients with Low
Baseline PlAtelet CouNts Diagnosed With Myeloﬁbrosis), a phase Ib
dose-ﬁnding study of ruxolitinib in patients with platelet counts of
50 109/L to 99 109/L, revealed no dose-limiting toxicities at the
doses tested to date (ie,  10 mg twice daily in patients with platelet
counts of 75 109/L to 99 109/L and 5 mg twice daily in patients
with platelet counts of 50  109/L to 74  109/L).44
Experience With Ruxolitinib in Clinical Practice
Important insight into the treatment effects of ruxolitinib in
patients with MF has recently come from clinical experience at
single institutions inside the United States, including Mayo Clinic,
Scottsdale,45 and Stanford University School of Medicine,46 and
large support programs outside the United States, including a
compassionate-use program by the French Intergroup of Myelopro-
liferative Neoplasms (FIM)47 and the international Individual Pati-
ent Supply Program (IPSP).48 Overall, the clinical experience with
these unselected patient populations conﬁrms the clinical beneﬁts of
ruxolitinib observed in the phase III COMFORT trials. The IPSP,
which included requests for ruxolitinib by > 800 physicians in 48
countries, approved access to the drug for at least 1240 patients
by December 2012. Of 639 patients enrolled before February 2012,
381 had available follow-up data. Most of these patients experienced
reductions in spleen size (201 of 247 evaluable patients [81.4%]) or
constitutional symptoms (151 of 203 [74.4%]), and most patients
who experienced reductions in spleen size also experienced symptom
improvement (131 of 162 [80.1%]).48 Safety proﬁles were compa-
rable with those reported in the COMFORT trials.48Clinical Lymphoma, Myeloma & Leukemia December 2013Conclusion
Since the publication of the primary analysis data from the
COMFORT trials in March 2012, both long-term follow-up data
from these trials and increasing clinical practice experience with
ruxolitinib therapy in unselected patient populations with MF
conﬁrm the previously established efﬁcacy and tolerability proﬁle
of ruxolitinib, ie, clinically meaningful improvement of disease-
associated splenomegaly and symptoms, improvement in health-
related QoL measures, and overall good tolerability. In general,
dose modiﬁcations and red blood cell transfusions appear to
be effective in managing treatment-related thrombocytopenia
and anemia. Preliminary data from studies43,44 suggest that up-
titration from a low dose (5 mg twice daily) may be a promising
strategy in patients with low platelet counts to achieve ﬁnal doses
of ruxolitinib that are both effective and well tolerated. Updated
results from the phase II study of ruxolitinib in patients with MF
who have low platelet counts provided the basis for the recent
approval by the United States Food and Drug Administration of
a new recommended starting dose of ruxolitinib 5 mg twice daily
for patients with baseline platelet counts of  50  109/L but <
100  109/L.41,49 The prescribing information updated in June
2013 also provides ﬂexibility for subsequent dose modiﬁcations
in this patient population, based on safety and efﬁcacy.41 The
results of the 2-year follow-up data from the COMFORT studies
in patients with platelet counts  100  109/L further suggest
that long-term ruxolitinib therapy provided durable efﬁcacy and
was not associated with unexpected adverse events. In addition,
there was no evidence of a withdrawal syndrome in patients who
discontinued treatment. New, 2-year survival data from the 2
COMFORT trials also suggest that ruxolitinib therapy may be
associated with a survival advantage for patients with intermediate-
2 and high-risk MF over those receiving no treatment (placebo)
and over those receiving traditional therapy (BAT). In
COMFORT-I, prolonged survival may in part be associated with
the metabolic improvements and weight gains observed in
ruxolitinib-treated patients, suggesting that alleviation of cachexia
may be 1 of the underlying mechanisms. Given the signiﬁcant
improvement in symptoms seen with ruxolitinib therapy, a
ruxolitinib-mediated survival advantage also would be consistent
with the established prognostic value of presence of symptoms in
patients with MF.8,21,22Acknowledgments
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